Cathay International Holdings Limited (CTI LN) H1: strong pharma & extract sales; Haizi and Fillderm weaker | Churchill China (CHH LN) Strong interims & upgrades. Prospects remain attractive | Oxford BioMedica (OXB LN) FDA approves Kymriah™ (CTL019) for paediatric r/r B-cell ALL | Restaurant Group (RTN LN)
Interims point to the investment thesis being on track
31 Aug 2017
N+1 Singer - Morning Song 31-08-2017
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Morning Song 31-08-2017
- Published:
31 Aug 2017 -
Author:
N+1 Singer Team -
Pages:
11
Cathay International Holdings Limited (CTI LN) H1: strong pharma & extract sales; Haizi and Fillderm weaker | Churchill China (CHH LN) Strong interims & upgrades. Prospects remain attractive | Oxford BioMedica (OXB LN) FDA approves Kymriah™ (CTL019) for paediatric r/r B-cell ALL | Restaurant Group (RTN LN)
Interims point to the investment thesis being on track